GSK stock declined 3% despite beating Q1 earnings estimates. Analysts note legal provisions contributed half the beat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results